quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:25:43·35d
ANALYSTRating
Aligos Therapeutics Inc. logo

Jefferies resumed coverage on Aligos Therapeutics with a new price target

ALGS· Aligos Therapeutics Inc.
Health Care
Original source

Companies

  • ALGS
    Aligos Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 19UpdateJefferies$48.00
  • Aug 18UpdateH.C. Wainwright$50.00
  • Aug 19UpdateH.C. Wainwright$75.00
  • Jan 6UpdatePiper Sandler$3.00
  • Jan 6UpdateJefferies$3.00
  • Mar 23UpdatePiper Sandler$4.00

Related

  • SEC2d
    SEC Form 8-K filed by Aligos Therapeutics Inc.
  • PR8d
    Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
  • SEC9d
    SEC Form 8-K filed by Aligos Therapeutics Inc.
  • PR9d
    Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
  • INSIDER43d
    SEC Form 4 filed by Officer Symons Julian A.
  • INSIDER43d
    SEC Form 4 filed by Aligos Therapeutics Inc.
  • INSIDER43d
    SEC Form 4 filed by Aligos Therapeutics Inc.
  • INSIDER43d
    SEC Form 4 filed by Principal Accounting Officer Aneja Nikhil
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022